Outcome and medical costs of patients with invasive aspergillosis and acute myelogenous leukemia-myelodysplastic syndrome treated with intensive chemotherapy: An observational study

Clinical Infectious Diseases

Volumn 47, Issue 12, 2008, Pages 1507-1512

  Slobbe, Lennert ^a   Polinder, Suzanne ^a   Doorduijn, Jeanette K ^a   Lugtenburg, Pieternella J ^a   El Barzouhi, Abdelilah ^a   Steyerberg, Ewout W ^a   Rijnders, Bart J A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTILEUKEMIC AGENT; ANTINEOPLASTIC AGENT; FLUCONAZOLE; GALACTOMANNAN; VORICONAZOLE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; ASPERGILLOSIS; COST OF ILLNESS; EARLY DIAGNOSIS; FEMALE; HEALTH CARE COST; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; INCIDENCE; LUNG LAVAGE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; NEUTROPHIL; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTIFUNGAL AGENTS; ASPERGILLOSIS; DRUG THERAPY; FEMALE; HEALTH CARE COSTS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; PYRIMIDINES; TREATMENT OUTCOME; TRIAZOLES;

EID: 56749174734     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/591531     Document Type: Article

References (27)

1. Denning DW. Invasive aspergillosis. Clin Infect Dis 1998; 26:781-803.
2. Denning DW. Therapeutic outcome in invasive aspergillosis. Clin Infect Dis 1996; 23:608-15.
3. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001; 32:358-66.
4. Patterson TF, Kirkpatrick WR, White M, et al.; I3 Aspergillus Study Group. Invasive aspergillosis: disease spectrum, treatment practices, and outcomes. Medicine (Baltimore) 2000; 79:250-60.
5. Perfect JR, Cox GM, Lee JY, et al. The impact of culture isolation of Aspergillus species: a hospital-based survey of aspergillosis. Clin Infect Dis 2001; 33:1824-33.
6. Pfaller MA, Pappas PG, Wingard JR. Invasive fungal pathogens: current epidemiological trends. Clin Infect Dis 2006; 43:s3-14.
7. Maschmeyer G, Haas A, Cornely OA. Invasive aspergillosis: epidemiology, diagnosis and management in immunocompromised patients. Drugs 2007; 67:1567-601.
8. Maertens J, Theunissen K, Verhoef G, et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 2005; 41:1242-50.
9. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347:408-15.
10. Schwartz S, Ruhnke M, Ribaud P, et al. Improved outcome in central nervous system aspergillosis, using voriconazole treatment. Blood 2005; 106:2641-5.
11. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007; 356:348-59.
12. Dutch-Belgian Cooperative Trial Group for Hematololy Oncology. Available at: http://www.hovon.nl. Accessed 16 May 2008.
13. Breems DA, Van Putten WL, Huijgens PC, et al. Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol 2005; 23:1969-78.
14. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003; 21:4642-9.
15. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46:1813-21.
16. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddard GL. Methods for the economic evaluation of health care programmes. 2nd ed. Oxford, England: Oxford University Press, 1997.
17. Gold MR, Siegel JE, Russel LB, Weinstein MC. Cost-effectiveness in health and medicine. Oxford, England: Oxford University Press, 1996.
18. Oostenbrink JB, Bouwmans CAM, Koopmanschap MA, Rutten FFH. Handleiding voor kostenonderzoek; methoden en standaard kostprijzen voor economische evaluaties in de gezondheidszorg. Diemen, The Netherlands: College voor Zorgverzekeringen, 2004.
19. Becker MJ, Lugtenburg EJ, Cornelissen JJ, Van Der Schee C, Hoogsteden HC, De Marie S. Galactomannan detection in computerized tomography-based broncho-alveolar lavage fluid and serum in haematological patients at risk for invasive pulmonary aspergillosis. Br J Haematol 2003; 121:448-57.
20. Meersseman W, Lagrou K, Maertens J, et al. Galactomannan in bronchoalveolar lavage fluid: a tool for diagnosing aspergillosis in intensive care unit patients. Am J Respir Crit Care Med 2008; 177:27-34.
21. Sanguinetti M, Posteraro B, Pagano L, et al. Comparison of real-time PCR, conventional PCR, and galactomannan antigen detection by enzyme-linked immunosorbent assay using bronchoalveolar lavage fluid samples from hematology patients for diagnosis of invasive pulmonary aspergillosis. J Clin Microbiol 2003; 41:3922-5.
22. Nguyen MH, Jaber R, Leather HL, et al. Use of bronchoalveolar lavage to detect galactomannan for diagnosis of pulmonary aspergillosis among nonimmunocompromised hosts. J Clin Microbiol 2007; 45:2787-92.
23. Wingard JR, Ribaud P, Schlamm HT, Herbrecht R. Changes in causes of death over time after treatment for invasive aspergillosis. Cancer 2008; 112:2309-12.
24. Cornely OA, Maertens J, Bresnik M, et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 2007; 44:1289-97.
25. Maertens J, Herbrecht R, Akan H, et al. Caspofungin as first-line therapy of invasive aspergillosis in haematological patients: impact of baseline characteristics on response rate at end of treatment and survival [abstract P1016]. In: Program and abstracts of the 18th European Congress of Clinical Microbiology and Infectious Diseases (Barcelona). 2008.
26. Zaoutis TE, Heydon K, Chu JH, Walsh TJ, Steinbach WJ. Epidemiology, outcomes, and costs of invasive aspergillosis in immunocompromised children in the United States, 2000. Pediatrics 2006; 117:e711-6.
27. Rijnders BJ, Cornelissen JJ, Slobbe L, et al. Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial. Clin Infect Dis 2008; 46:1401-8.